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Summary
NF-kB essential modulator (NEMO), the regulatory
subunit of the IkB kinase (IKK) that activates NF-kB,
is essential for NF-kB activation [1]. NEMO was re-
cently found to contain a region that preferentially
binds Lys (K)63-linked but not K48-linked polyubiqui-
tin (polyUb) chains, and the ability of NEMO to bind
to K63-linked polyUb RIP (receptor-interacting pro-
tein) is necessary for efficient tumor necrosis factor
a (TNFa)-induced NF-kB activation [2, 3]. Optineurin
is a homolog of NEMO, andmutations in the optineurin
gene are found in a subset of patients with glaucoma
[4], a neurodegenerative disease involving the loss
of retinal ganglion cells [5]. Although optineurin
shares considerable homology with NEMO, in resting
cells, it is not present in the high-molecular-weight
complex containing IKKa and IKKb, and optineurin
cannot substitute for NEMO in lipopolysaccharide
(LPS)-induced NF-kB activation [6]. On the other
hand, the overexpression of optineurin blocks the pro-
tective effect of E3-14.7K on cell death caused by the
overexpression of TNFa receptor 1 (TNFR1) [7]. Here
we show that optineurin has a K63-linked polyUb-
binding region similar to that of NEMO, and like
NEMO, it bound K63- but not K48-linked polyUb. Opti-
neurin competitively antagonized NEMO’s binding to
polyUb RIP, and its overexpression inhibited TNFa-
induced NF-kB activation. This competition occurs at
physiologic protein levels because microRNA silenc-
ing of optineurin resulted in markedly enhanced
TNFa-induced NF-kB activity. These results reveal
a physiologic role for optineurin in dampening TNFa
signaling, and this role might provide an explanation
for its association with glaucoma.
Results and Discussion
Although optineurin cannot restore NF-kB activation in
NF-kB essential modulator (NEMO)-deficient cells, the
high degree of homology between the two proteins nev-
ertheless suggests that it might modulate IkB kinase
(IKK) activation. Therefore, we asked whether ectopi-
cally expressed optineurin can affect NF-kB activation.
Because the overexpression of TRAF2 or RIP (recep-
tor-interacting protein) alone can activate NF-kB [8, 9],
an NF-kB reporter construct along with cDNA vectors
*Correspondence: jda@pop.nci.nih.govcontaining TRAF2 or RIP in the absence or presence of
optineurin were introduced into 293 cells. NF-kB in-
duced by both TRAF2 (Figure 1A) and RIP (Figure 1B)
was profoundly inhibited by the coexpression of opti-
neurin. This inhibition was proximal to IKK because op-
tineurin had no effect on NF-kB activation caused by
a constitutively active IKKb mutant (IKKb-CA, S178E,
S181E) [10] (Figure 1C). Therefore, optineurin’s inhibi-
tory effect is likely to be at an early stage in the signaling
pathway leading to NF-kB activation, perhaps at the
level of the signalosome assembled at or near the
plasma membrane.
The K63-linked polyubiquitin (polyUb)-binding region
of NEMO has recently been found to encompass
a coiled-coil domain (CC2), a linker region, and a leucine
zipper (LZ) [2, 3]. A BLAST search with a full-length
NEMO sequence revealed that its overall homology
with optineurin is 53%, and it is 64% in the area corres-
ponding to the NEMO polyUb-binding region (Table S1
and Figure S4 in the Supplemental Data available
online), prompting us to ask whether optineurin binds
polyUb as well. NEMO binds to multiubiquitin arranged
in a head-to-tail fashion in addition to K63-linked polyUb,
most likely because of similar three-dimensional confor-
mations [2, 11]. Therefore, 35S-labeled in vitro-translated
proteins were offered to recombinant GST-ubiquitin-
coated beads (Figure 2A). As previously shown [2],
GST-ubiquitin brought down NEMO, the efficacy in-
creasing in proportion to the number of ubiquitin moie-
ties. Notably, GST-ubiquitin brought down optineurin
in a similar fashion. A direct comparison of NEMO and
optineurin was made: 6His-tagged versions were used
to pull down K63-linked polyUb (Figure 2B). Whereas
both proteins brought down K63-linked polyUb, opti-
neurin was clearly better than NEMO, implying that it
has a higher binding affinity. Moreover, a mutation in
the optineurin linker region analogous to one in NEMO
that disrupts polyUb binding, D474N (D311N in NEMO),
also abolished its binding to K63-linked polyUb. Both
proteins had the same specificity in that they failed to
bring down appreciable amounts of K48-linked polyUb
([2] and data not shown). Thus, optineurin and NEMO
represent a family of polyUb-binding proteins with
selectivity for chains with K63 linkages.
The overlapping polyUb-binding selectivity of the two
proteins raised the possibility that they might share
binding partners. One such NEMO-binding protein in
the tumor necrosis factor a (TNFa) signaling pathway
is ubiquitinated RIP [2]. Lysate from HeLa cells that
had been stimulated or not with TNFa were subjected
to pull-down with similar amounts (Figure 3A, left panel)
of GST-optineurin, GST-optineurinD474N, or GST-NEMO
(Figure 3A, right panel). None of the GST fusion proteins
bound RIP in lysates from unstimulated cells. However,
within 5 min of stimulation with TNFa, both GST-NEMO
and GST-optineurin pulled down ubiquitinated, but not
unmodified, RIP (Figure 3A, right panel). Furthermore,
the polyUb-binding defective GST- optineurinD474N
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1439Figure 1. Optineurin Inhibits TRAF2- or RIP-Induced NF-kB Activation
(A) Vectors expressing wild-type optineurin and/or TRAF2 were cotransfected with NF-kB reporter and b-galactosidase plasmids into 293 cells
and cultured for 20 hr. The cells were lysed, and luciferase activity was measured and normalized to b-galactosidase activity. Error bars represent
standard error of the mean of triplicate samples.
(B) Vectors expressing wild-type optineurin and/or RIP with reporter constructs were cotransfected into 293 cells as above, and reporter assays
were performed.
(C) Vectors expressing wild-type optineurin and/or constitutively active IKKb (IKKb-CA) with reporter constructs were cotransfected into 293
cells as above, and reporter assays were performed.failed to bring down ubiquitinated RIP, indicating that
recognition of polyUb chains is necessary for optineurin
to bind RIP with high affinity.
Figure 2. Optineurin Binds K63-Linked polyUb Chains
(A) In vitro-translated and 35S-labeled optineurin or NEMO was incu-
bated with glutathione-sepharose beads bound GST, GST-monoUb,
GST-diUb, or GST-triUb for 2 hr at 4C. The bound proteins were
eluted and resolved by sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE) and visualized with a PhosphorImager.
After exposure, the gels were stained with Coomassie blue to verify
equal loading of GST fusion proteins.
(B) Cobalt bead-bound 6His-optineurin, 6His-optineurinD474N, 6His-
NEMO, or 6His-NEMOD311N was incubated with K63-linked polyUb
(pUb). The beads were washed, and the proteins were eluted and re-
solved by SDS-PAGE; immunoblotting with 6His antibody and strip-
ping and reblotting of the same membrane with anti-Ub followed.
Two percent of the amount of input K63-linked polyUb used for
each reaction is shown.For determining whether optineurin binds polyubiqui-
tinated RIP in vivo, HeLa cells were stimulated with
TNFa and lysates were immunoprecipitated with anti-
optineurin (Figure 3B). In this setting, a small amount
of unmodified RIP coimmunoprecipitated with endo-
genous optineurin in the absence of stimulation. After
stimulation, a large amount of ubiquitinated RIP was
coimmunoprecipitated. Despite the fact that only
a very small amount of RIP was polyubiquitinated in
TNFa-stimulated cells (undetectable when whole-cell ly-
sates were blotted) (Figure 3B), it was highly enriched in
the material coimmunoprecipitated with optineurin, indi-
cating that optineurin preferentially interacts with ubiq-
uitin-modified RIP. The binding by optineurin to polyubi-
quitinated RIP is not cell-type dependent; similar results
were obtained with lysates from TNFa-stimulated
mouse embryonic fibroblasts (MEFs) (Figure S1).
Because NEMO and optineurin both bind to polyubi-
quitinated RIP, we asked whether they interacted with
one another in the TNFa receptor (TNFR) signaling com-
plex. HeLa cells were stimulated with TNFa, and lysates
were immunoprecipitated with anti-optineurin or anti-
NEMO (Figure 4A). Both NEMO and optineurin coimmu-
noprecipitated with polyubiquitinated RIP. Surprisingly,
however, optineurin and NEMO were not found in the
same complexes when immunoprecipitates of one
were immunoblotted for the other. Therefore, although
both optineurin and NEMO bind polyubiquitinated RIP,
they do not bind the same molecules of RIP. This exclu-
sivity of binding suggested that optineurin and NEMO
might be competitive inhibitors of one another. For test-
ing this, GST-NEMO was incubated with cell lysates
from TNFa-stimulated HeLa cells, to which increasing
amounts of soluble His-tagged optineurin was added
(Figure 4B). The amount of polyubiquitinated RIP pulled
down by GST-NEMO decreased as optineurin was ti-
tered into the lysate, and it was substantially reduced
when an equivalent amount of optineurin was added
and diminished further when more optineurin was pres-
ent. For addressing the role of polyUb binding in the
competition, the activity of wild-type optineurin and op-
tineurinD474N was compared; the latter failed to inhibit
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1440Figure 3. Optineurin Binds to Polyubiquitinated RIP
(A) Lysates of HeLa cells stimulated or not with 20 ng/ml TNFa for 5 min were incubated with glutathione Sepharose beads coated with GST, GST-
optineurin, GST- optineurinD474N, or GST-NEMO. The bound proteins were resolved by SDS-PAGE and immunoblotted with anti-RIP. The posi-
tion of unmodified RIP in the cell lysate is indicated with an arrow. An equal amount of GST fusion proteins were used, as judged by Coomassie-
blue staining (left panel).
(B) Lysates of HeLa cells stimulated with TNFa for the indicated times were immunoprecipitated with anti-optineurin. The cell lysate (5% of input)
and immunoprecipitates were resolved by SDS-PAGE and immunoblotted with anti-RIP. Because RIP and optineurin have similar molecular
weights, the amount of immunoprecipitated optineurin in this experiment was quantified in a gel loaded identically and run in parallel. ‘‘ns’’ in-
dicates a nonspecific band.the binding of NEMO to polyubiquitinated RIP (Fig-
ure 4C). Possible competition between NEMO and opti-
neurin in vivo was assessed by looking for displacement
of RIP from NEMO in cells expressing varying amounts
of optineurin (Figure 4D). The amount of polyUb RIP
that coimmunoprecipitated with NEMO in TNFa-
stimulated cells decreased as the amount of optineurin
increased. Consistent with its affinity for polyUb RIP, op-
tineurin was recruited to the TNFR1 signaling complex in
TNFa-stimulated wild-type cells but not in cells deficient
in RIP (Figure 4E). Additionally, the introduction of opti-
neurin resulted in a decrease in the amount of NEMO
that coimmunoprecipitated with TNFR1 after TNFa stim-
ulation, consistent with its ability to compete with NEMO
in the signaling complex (Figure 4F). It is notable that the
initial binding of both NEMO and optineurin to TNFR1
followed similar kinetics, first being detected between
1 and 5 min of stimulation. Furthermore, another compo-
nent of the TNF proximal signaling pathway, TRADD
(TNFR1-associated death domain), but not IKKa coim-
munoprecipitated with optineurin after TNFa stimulation
(Figure 4G). Taken together, these data support the no-
tion that optineurin and NEMO compete with each other
for polyUb RIP in the same TNFa-induced signaling
complex.
Because the ability of NEMO to bind polyubiquitinated
RIP is important for TNFa-induced NF-kB activation
[2, 3], it was possible that competition between opti-
neurin and NEMO could explain why optineurin inhibited
TRAF2- or RIP-induced NF-kB activation. For address-
ing this, cDNA vectors containing wild-type optineurin
or optineurinD474N along with an NF-kB reporter were in-
troduced into 293 cells that were stimulated or not with
TNFa (Figure 5A). Optineurin had a substantial inhibitory
effect on NF-kB activation after TNFa stimulation,
whereas the optineurin mutant incapable of binding
K63-linked polyUb did not. Overexpression of optineurin
also prevented the TNFa-induced upregulation of en-
dogenous IL-6, a gene product whose expression is de-
pendent on NF-kB (Figure 5B). The transient expressionof optineurin also prevented TNFa-induced IkBa degra-
dation (Figure 5C). The observation that optineurin over-
expression resulted in higher basal IkBa levels is consis-
tent with the lower basal NF-kB activity observed in
Figure 5A and Figure S2A. For the determination of
whether optineurin inhibits NF-kB activation at physio-
logic levels, endogenous optineurin expression was sta-
bly reduced (knocked down) in 293 cells with microRNA
(miRNA). Optineurin levels were markedly reduced in
cells expressing optineurin-specific miRNA, compared
to a nonspecific control (Figure 5D). Importantly,
TNFa-induced NF-kB activity was greatly augmented
when optineurin levels were reduced (Figure 5E). Con-
sistent with the specific silencing of optineurin, transient
re-expression in these cells of optineurin that lacked the
30 untranslated region (UTR) targeted by the miRNA in-
hibited TNFa-induced NF-kB activation (Figure S2A). Al-
though the silencing was not as complete, treatment
with a mixture of small interfering RNAs (siRNAs) target-
ing different sequences also resulted in enhanced NF-
kB activation (Figure S2B). Thus, at normal levels, opti-
neurin strongly inhibits TNFa-signaled NF-kB activation.
Most studies of optineurin have focused on its binding
partners and, to a lesser extent, possible functional
properties. Optineurin interacts with adenovirus
E3-14.7K [7], Huntington [12], RAB8 [13], transcription
factor IIIA [14], and myosin VI [15]. siRNA studies have
suggested that optineurin plays a role in Golgi integrity
and the exocytosis of vesicular-stomatitis-virus G pro-
tein [15]. Optineurin normally resides in the cytoplasm,
but it has recently been shown to shuttle to the nucleus
in NIH 3T3 cells stimulated with H2O2, although the bio-
logical significance of this is not yet known. Despite the
enumeration of these individual activities, how opti-
neurin might regulate cell functions is unclear, and its
role in glaucoma is unexplained.
The finding that optineurin, like NEMO, has a predilec-
tion for binding K63-linked polyUb chains led to the ob-
servation that it is a competitive antagonist of NEMO
that at physiologic levels dampens NF-kB activation in
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1441Figure 4. Optineurin Competes with NEMO to Bind to Polyubiquitinated RIP
(A) Lysates of HeLa cells stimulated or not with 20 ng/ml TNFa for 5 min were immunoprecipitated with anti-optineurin or anti-NEMO. The cell
lysates (5% of input) and immunoprecipitates were resolved by SDS-PAGE and immunoblotted with anti-RIP, anti-optineurin, and anti-NEMO.
‘‘ns’’ indicates a nonspecific band.
(B and C) Lysates of HeLa cells stimulated with TNFa were incubated with glutathione Sepharose beads coated with GST or GST-NEMO in the
presence of increasing amounts of His-tagged optineurin or optineurinD474N in solution. The relative amount of 6xHis-optineurin to GST-NEMO in
(B) was 1:1, 10:1, 100:1 and in (C) was 1:1 and 10:1. The bound proteins were eluted and resolved by SDS-PAGE and immunoblotted with anti-
RIP. Equal amount of GST-NEMO were used for each pull-down, as judged by Ponceau S staining of the same membrane.
(D) Forty hours after transfection of 293 cells with the indicated amounts of optineurin plasmid, the cells were stimulated with TNFa, lysed, and
immunoprecipitated with anti-NEMO. The immunoprecipitates were immunoblotted with anti-RIP or anti-NEMO. ‘‘ns’’ indicates a nonspecific
band.
(E) Lysates of RIP+/+ and RIP2/2 MEFs were stimulated with mouse TNFa for 10 min, immunoprecipitated with anti-TNFR1, and immunoblotted
with anti-RIP and anti-optineurin.
(F) MEFs were infected with virus encoding 6His-OPTN and after 48 hr were stimulated with mouse TNFa for the indicated times. Lysates were
immunoprecipitated with anti-TNFR1 and immunoblotted with anti-NEMO, anti-6His, and anti-TNFR1.
(G) Lysates of HeLa cells stimulated with TNFa were immunoprecipitated with anti-optineurin or anti-NEMO and immunoblotted with antibodies
to the indicated molecules.response to TNFa. The simultaneous binding of opti-
neurin and NEMO to the same signaling complex with
similar kinetics indicates that optineurin attenuates sig-
naling from the beginning and therefore elevates the
threshold of activation for NF-kB. Optineurin is a regu-
lated gene, its expression being induced by TNFa as
well as type 1 and type 2 interferons (IFNs) [6, 7]. It
is noteworthy, therefore, that the pretreatment of cells
with TNFa for 18 hr, a time sufficient to allow optineurin
upregulation [6], has been found to reduce subsequent
TNFa-induced NF-kB activation [16]. Furthermore, pre-
treatment with IFN-g strongly inhibits NF-kB activation
by RANKL (receptor activator of NF-kB ligand) [17],
a member of the TNF superfamily. IFNs also sensitizetumor cells to TNFa- or TRAIL (TNF-related apoptosis-
inducing ligand)-induced apoptosis by inhibiting NF-kB
activation [18–21]. The present results suggest that the
upregulation of optineurin is the cause of cytokine
crosstolerance between IFNs and TNF family members
such as TNFa, RANKL, and TRAIL.
Glaucoma is a neurodegenerative disease involving
the loss of retinal ganglion cells [5]. Optineurin muta-
tions were initially reported to account for 16.7% of nor-
mal-tension primary open-angle glaucoma [4], although
subsequent studies have found the degree of associa-
tion in different populations to be considerably less
[22–24]. The association is autosomal dominant, consis-
tent with, although not proof of, a gain-of-function
Current Biology Vol 17 No 16
1442mutation. It has been postulated that neuron loss result-
ing from glutamate receptor excitotoxicity is a common
mechanism for glaucoma and other neurodegenerative
disorders such as Parkinson’s, Alzheimer’s, and multi-
ple sclerosis [25], and a significant association between
glaucoma and other neurodegenerative diseases has
been reported [26]. TNFa upregulates the expres-
sion of the receptor for a-amino-3-hydroxy-5-methyl-
4-isoxazolepropionic acid (AMPAR), which represents
one major excitatory subgroup of glutamate receptors,
in neuronal cells [27] and synergizes with TNFa to
enhance excitotoxic cell death, both responses being
dependent on NF-kB activity [28]. The upregulated ex-
pression of TNFa by astrocytes is observed in glau-
comatous optic nerve heads [29], and, interestingly,
the inhibition of NF-kB activation in neuronal cells ame-
liorates the pathology of murine experimental allergic
Figure 5. Optineurin Inhibits NF-kB Activation Induced by TNFa
(A) Vectors containing wild-type optineurin or optineurinD474N were
cotransfected with NF-kB and b-galactosidase reporter plasmids
into 293 cells for 20 hr. After 5 hr of incubation with TNFa (20 ng/ml),
the cells were lysed, and luciferase activity was measured and nor-
malized to b-galactosidase activity. Error bars represent standard
error of the mean of triplicate samples.
(B) Twenty-four hours after transfection with an optineurin expres-
sion vector, 293 cells were stimulated with TNFa and IL-6 was mea-
sured 20 hr later.
(C) 293 cells were transfected with 6His-optineurin and Flag-IkBa
expression vectors. After 20 hr, the cells were stimulated or not for
15 min with TNFa, lysed, and immunoblotted with anti-Flag, anti-
6His, and anti-actin.
(D) Optineurin levels were stably reduced in 293 cells by the trans-
fection of a plasmid containing miRNA targeting optineurin, and
blasticidin selection for 2 weeks followed. A miRNA plasmid contain-
ing a nontargeting sequence was used as a negative control. Knock-
down efficiency was verified by the immunoblotting of the whole-cell
lysate with anti-optineurin.
(E) NF-kB reporter and b-galactosidase reporter plasmids were co-
transfected into optineurin knockdown and control cells for 20 hr.
After 5 hr of incubation with TNFa (1 or 10 ng/ml), the cells were
lysed, and luciferase activity was measured and normalized to
b-galactosidase activity.encephalomyelitis [30]. We have found that the overex-
pression of optineurin dramatically inhibits TNFa-
induced NF-kB activation in a neuronal cell line (data
not shown), consistent with a model in which the reduc-
tion of functional optineurin might render neural cells hy-
persensitive to TNFa- and AMPA-induced cell death. It
should be noted that two mutations in optineurin in par-
ticular are likely to be disease causing. One is truncation
resulting from the insertion of a premature stop codon
and the loss of the polyUb-binding domain [4]. As ex-
pected, this mutation (optineurintrunc) rendered opti-
neurin unable to bind K63-linked polyUb or polyubiquiti-
nated RIP (unpublished data). The other mutation is
a single amino acid substitution at residue 50 (optineur-
inE50K) [31, 4]. This mutation is far from the polyUb-
binding domain, and in fact we found that recombinant
optineurin containing this mutation bound polyubiquiti-
nated RIP and inhibited TNFa-induced NF-kB activation
like wild-type optineurin (unpublished data). It should be
noted, however, that optineurinE50K protein levels were
found to be markedly reduced in cells from glaucoma
patients [4], raising the possibility that it is the reduction
in expression, rather than altered function, that contrib-
utes to the development of glaucoma.
NEMO-mediated NF-kB activation is involved in many
signaling pathways, including that of the T cell receptor
(TCR) [32], B cell receptor (BCR) [33], receptors for proin-
flammatory cytokines and interleukins [34], and Toll-like
receptors [1]. The ability of optineurin to inhibit NEMO-
dependent NF-kB activation raises the possibility that
optineurin possibly plays roles in these signaling path-
ways as well. In fact, the overexpression of optineurin re-
sulted in the inhibition of IL-1-induced NF-kB activation
(unpublished data). The close relationship between acti-
vation of NF-kB, inflammation, and neoplasia is well es-
tablished [35]. By inhibiting IKK and NF-kB activation,
optineurin might therefore have regulatory functions in
chronic inflammation and cancer development.
Supplemental Data
Experimental Procedures, four figures, and one table are available at
http://www.current-biology.com/cgi/content/full/17/16/1438/DC1/.
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